Efficacy and safety of microwave ablation combined with bevacizumab in the treatment of epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer
You Yuanli
Wang Xiuqing
Yang Mingxing
Dong Wen
Abstract：Objective To explore the synergistic efficacy and safety of microwave ablation combined with bevacizumab in epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)-resistant advanced non-small cell lung cancer(NSCLC).Methods A retrospective analysis was performed on the clinical data of 82 patients with advanced non-squamous NSCLC who developed resistance to EGFR-TKI treatment and were admitted to Hainan Cancer Hospital from January 2022 to April 2025.According to the treatment regimens,the patients were divided into the combination group and the control group,with 41 cases in each group.The control group received pemetrexed/carboplatin chemotherapy,while the combination group was treated with microwave ablation plus bevacizumab combined with pemetrexed/carboplatin chemotherapy.The short-term efficacy,dynamic changes of serum tumor markers,long-term survival benefits and safety were compared between the two groups.Results The objective response rate and disease control rate in the combination group were significantly higher than those in the control group[65.8％(27/41)vs 34.2％(14/41),90.2％(37/41)vs 68.3％(28/41)](both P＜0.05).After treatment,the levels of carcinoembryonic antigen and cytokeratin 19 fragment in both groups were lower than those before treatment,and the levels in the combination group were significantly lower than those in the control group(all P＜0.05).The median progression-free survival(mPFS)in the combination group was 8.5 months(95％confidence interval:7.803-10.397),while that in the control group was 5.3 months(95％confidence interval:4.076-6.524).The mPFS in the combination group was significantly longer than that in the control group(hazard ratio=0.46,P＜0.01).There was no statistically significant difference in the incidence of grade 3 or above adverse reactions between the combination group and the control group(P＞0.05).Conclusion Microwave ablation combined with bevacizumab exerts a certain synergistic effect in patients with EGFR-TKI resistance,improves the response of tumor markers,prolongs PFS,and has a controllable safety profile,which provides a novel integrated treatment strategy for advanced NSCLC.
Keywords：Non-small cell lung cancerMicrowave ablationBevacizumabEpidermal growth factor receptor tyrosine kinase inhibitors resistance
Publication Date：2026-03-18
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 344-348 )